{
    "clinical_study": {
        "@rank": "82378", 
        "arm_group": [
            {
                "arm_group_label": "Alpha1 Antitrypsin (Glassia)", 
                "arm_group_type": "Experimental", 
                "description": "60 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Alpha-1 Antitrypsin (Glassia)", 
                "arm_group_type": "Experimental", 
                "description": "120 mg/kg body weight"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A Pivotal, Phase II-III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study\n      Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia\u00ae] in the\n      Treatment of New Onset Type-1 Diabetes.\n\n      A sample size of 192 patients is planned, with 64 patients randomized to each of the three\n      study groups.\n\n      The study objectives are:\n\n        -  To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes\n\n        -  To assess the safety  and tolerability of intravenous AAT in new onset Type 1 Diabetes\n           pediatric and young adult population."
        }, 
        "brief_title": "Phase II-III Study to Evaluate the Efficacy and Safety of Glassia\u00ae in Type-1 Diabetes", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "New Onset Type-1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Subject (or parent/guardian) willing and able to sign an informed consent\n\n          -  Age 8-25 (inclusive) years\n\n          -  Recently diagnosed with T1DM\n\n          -  Basal C-peptide \u2265 0.2 pmol/mL\n\n          -  Positive for at least one diabetes-related autoantibody\n\n          -  Ability and consent to comply with completion of patient diary\n\n          -  No significant abnormalities in serum hematology, serum chemistry\n\n          -  No significant abnormalities in urinalysis\n\n          -  No significant abnormalities in ECG\n\n          -  For women of child bearing potential,  non-pregnant, non-lactating female patients\n\n        Main Exclusion Criteria:\n\n          -  IgA deficient subjects\n\n          -  Subjects who have received an active/ live virus vaccine within 4 weeks of the\n             screening date\n\n          -  Subjects who have received treatment with corticosteroid medication within 2 months\n             prior to screening or any immunosuppressant or cytostatic agent within 6 months prior\n             to screening\n\n          -  Individuals with a history of severe immediate hypersensitivity reactions, including\n             anaphylaxis, to plasma products\n\n          -  Clinically significant intercurrent illnesses\n\n          -  Pregnant or lactating women\n\n          -  Current use of any medication known to influence glucose tolerance\n\n          -  Current or prior (within the last 60 days prior to screening visit) use of metformin,\n             sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV\n             inhibitors or amylin."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005848", 
            "org_study_id": "Kamada-AAT(IV)-011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Alpha1 Antitrypsin (Glassia)", 
                    "Alpha-1 Antitrypsin (Glassia)"
                ], 
                "intervention_name": "Alpha-1 Antitrypsin", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Humman Alpha-1 Antitrypsin", 
                    "Alpha-1 Proteinase Inhibitor", 
                    "API", 
                    "AAT"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor", 
                "Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type-1 Diabetes", 
            "T1D", 
            "Diabetes Mellitus"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "elih@bgu.ac.il", 
                    "last_name": "Eli Hershkovitz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Beer Sheva", 
                        "country": "Israel"
                    }, 
                    "name": "Soroka Medical Center"
                }, 
                "investigator": {
                    "last_name": "Eli Hershkovitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "n_shehadeh@rambam.health.gov.il", 
                    "last_name": "Naim Shehadeh, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }, 
                    "name": "Rambam Medical Center"
                }, 
                "investigator": {
                    "last_name": "Naim Shehadeh, Prof., MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Yaell@clalit.org.il", 
                    "last_name": "Yael Lebenthal, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pethach Tikva", 
                        "country": "Israel"
                    }, 
                    "name": "Schneider Children's Medical Center"
                }, 
                "investigator": {
                    "last_name": "Yael Lebenthal, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rmarianna@gmail.com", 
                    "last_name": "Marianna Rachmiel, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Zerifin", 
                        "country": "Israel"
                    }, 
                    "name": "Assaf Harofe Medical Center"
                }, 
                "investigator": {
                    "last_name": "Marianna Rachmiel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II-III Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia\u00ae] in the Treatment of New Onset Type-1 Diabetes", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Beta cell function (measured by C peptide)", 
            "measure": "Beta cell function", 
            "safety_issue": "No", 
            "time_frame": "12 months from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005848"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Glycemic control expressed in HbA1c level", 
                "measure": "Glycemic control", 
                "safety_issue": "No", 
                "time_frame": "24 months from baseline"
            }, 
            {
                "measure": "Beta cell function", 
                "safety_issue": "No", 
                "time_frame": "24 months from baseline"
            }, 
            {
                "measure": "Insulin dose", 
                "safety_issue": "No", 
                "time_frame": "24 months from baseline"
            }, 
            {
                "measure": "Hypoglycemic episodes", 
                "safety_issue": "No", 
                "time_frame": "24 months from baseline"
            }, 
            {
                "description": "Adverse events, vital signs, physical examination", 
                "measure": "Safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "24 months from baseline"
            }
        ], 
        "source": "Kamada, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kamada, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}